Publication Name	World Journal of Gastroenterology
Manuscript ID	3456
Country	Japan

Received	2013-05-01 13:33
Peer-Review Started	2013-05-03 11:47
To Make the First Decision	2013-06-09 10:13
Return for Revision	2013-06-18 14:17
Revised	2013-06-30 15:37
Second Decision	2013-07-05 11:56
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-07-05 13:04
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-27 09:34
Publish the Manuscript Online	2013-09-14 11:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2
Manuscript Source	Invited Manuscript
All Author List	Ken Sato, Masatoshi Yanagisawa, Hiroaki Hashizume, Yuichi Yamazaki, Norio Horiguchi, Satoru Kakizaki and Masatomo Mori
Funding Agency and Grant Number	Funding Agency Grant Number Merck Sharp & Dohme, Tokyo, Japan Chugai Pharmaceutical Co., Ltd., Tokyo, Japan to Mori M
Corresponding Author	Ken Sato, MD, PhD, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. satoken@showa.gunma-u.ac.jp
Key Words	Hepatitis C; Genotype 2 and high viral loads; Interferon-based therapy; Highly intractable case; Extended therapy duration
Core Tip	The optimal therapy for 48-wk peginterferon-α-2b/ribavirin therapy-intractable hepatitis C patients with genotype 2 and high viral loads remains unknown. Our cases are notable in that 72-wk peginterferon-α-2a/ribavirin therapy may have been effective for these highly intractable cases. Additionally, the rebound phenomenon of serum transaminase after the 48-wk peginterferon-α-2b/ribavirin therapy and the resultant lower viral load compared to that before the 48-wk peginterferon-α-2b/ribavirin therapy might have influenced the treatment outcome. Thus, our cases highlight the importance of the results of the previous 48-wk peginterferon-α-2b/ribavirin therapy in the indication and timing of the administration of 72-wk peginterferon-α-2a/ribavirin in highly intractable cases.
Publish Date	2013-09-14 11:17
Citation	Sato K, Yanagisawa M, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2. World J Gastroenterol 2013; 19(34): 5754-5758
URL	http://www.wjgnet.com/1007-9327/full/v19/i34/5754.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i34.5754

Full Article (PDF)	WJG-19-5754.pdf
Manuscript File	3456-Review.docx
Answering Reviewers	3456-Answering reviewers.pdf
Copyright License Agreement	3456-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	3456-Language certificate.pdf
Peer-review Report	3456-Peer review.pdf
Scientific Editor Work List	3456-Scientific editor work list.doc